JMC Investment, along with Keosys’ Board of Directors, is pleased to announce that Mr. Francois Labarre has been named CEO of Keosys Medical Imaging and will oversee global operations for the Company. Mr. Labarre, who has been involved in the pharmaceutical industry for over 25 years having held executive positions for leading radiopharmaceutical companies including IBA, Amersham and Cis-Bio will also serve as a Board Director for Keosys Group.
“I am very proud to be joining Keosys and excited for the company to assert itself as a leading Imaging CRO for years to come” says Francois Labarre. “I have been very impressed by Keosys’ team and products since joining the company and look forward to working with our teams to continue developing our integrated imaging management system and processes to benefit of our customer base”.
Jerome Fortineau, Founder and former CEO of the Company, welcomes Mr. Labarre. Mr. Fortineau said, “Mr. Labarre’s experience is a great fit for Keosys and I am excited to welcome him to Keosys. With Francois’ arrival I will have the opportunity to stay very involved at Keosys, focusing on special projects and remaining an active Board member”.
“Francois has a track record of strong leadership in the healthcare industry “says Mr. Jean-Marie Painvin, Founder and CEO of JMC Investment who acquired Keosys Group in 2015. “Combined with his expertise in Molecular Imaging and his sales and marketing background, Francois is the perfect complement to the Keosys team and brings the industry expertise and methodology we need to execute the Company’s business vision”.
Since its creation in 2001, Keosys has built a rich expertise in medical imaging in a variety of therapeutic areas and modalities. The company has collaborated with academic partners as well as medical and pharmaceutical experts to design a state-of-the-art web-based imaging platform as well as associated services to the benefit of the Pharma Industry. As a leading Imaging CRO Keosys has all of the tools to help the Pharma Industry run international phase 2 and 3 Clinical Trials. The Company is headquartered in St. Herblain (France) with operations in the United-States and Singapore.
For more information please visit www.keosys.com